These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 21384334

  • 1. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study.
    Gabay C, Bel M, Combescure C, Ribi C, Meier S, Posfay-Barbe K, Grillet S, Seebach JD, Kaiser L, Wunderli W, Guerne PA, Siegrist CA, H1N1 Study Group.
    Arthritis Rheum; 2011 Jun; 63(6):1486-96. PubMed ID: 21384334
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
    Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM.
    Vaccine; 2010 Feb 17; 28(7):1740-5. PubMed ID: 20034605
    [Abstract] [Full Text] [Related]

  • 3. Antibody response after a single dose of an AS03-adjuvanted split-virion influenza A (H1N1) vaccine in heart transplant recipients.
    Meyer S, Adam M, Schweiger B, Ilchmann C, Eulenburg C, Sattinger E, Runte H, Schlüter M, Deuse T, Reichenspurner H, Costard-Jäckle A.
    Transplantation; 2011 May 15; 91(9):1031-5. PubMed ID: 21358365
    [Abstract] [Full Text] [Related]

  • 4. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age.
    Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P.
    Clin Infect Dis; 2010 Sep 15; 51(6):668-77. PubMed ID: 20687838
    [Abstract] [Full Text] [Related]

  • 5. Protective effect of A/H1N1 vaccination in immune-mediated disease--a prospectively controlled vaccination study.
    Adler S, Krivine A, Weix J, Rozenberg F, Launay O, Huesler J, Guillevin L, Villiger PM.
    Rheumatology (Oxford); 2012 Apr 15; 51(4):695-700. PubMed ID: 22171015
    [Abstract] [Full Text] [Related]

  • 6. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I, Roman F, Forgus S, Maes C, De Boever F, Dramé M, Gillard P, van der Most R, Van Mechelen M, Hanon E, Leroux-Roels G.
    Vaccine; 2010 Jan 08; 28(3):849-57. PubMed ID: 19835828
    [Abstract] [Full Text] [Related]

  • 7. Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children.
    Meier S, Bel M, L'huillier A, Crisinel PA, Combescure C, Kaiser L, Grillet S, Pósfay-Barbe K, Siegrist CA, H1N1 Epidemiology Study Group of Geneva.
    Vaccine; 2011 Apr 27; 29(19):3548-57. PubMed ID: 21419775
    [Abstract] [Full Text] [Related]

  • 8. Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients.
    Tremblay CL, Rouleau D, Fortin C, Toma E, Sylla M, Cyr L, Cote S, Baz M, Sampalis J, Trautman L, Sékaly RP, Boivin G.
    Vaccine; 2011 Feb 04; 29(7):1359-63. PubMed ID: 21185423
    [Abstract] [Full Text] [Related]

  • 9. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.
    Caillet C, Piras F, Bernard MC, de Montfort A, Boudet F, Vogel FR, Hoffenbach A, Moste C, Kusters I.
    Vaccine; 2010 Apr 19; 28(18):3076-9. PubMed ID: 20193791
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children.
    Scheifele DW, Ward BJ, Dionne M, Vanderkooi O, Langley JM, Dobson S, Li Y, Law B, Halperin SA, Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) Rapid Trials Investigators.
    Pediatr Infect Dis J; 2011 May 19; 30(5):402-7. PubMed ID: 21178654
    [Abstract] [Full Text] [Related]

  • 11. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice.
    Ribeiro AC, Guedes LK, Moraes JC, Saad CG, Aikawa NE, Calich AL, França IL, Carvalho JF, Sampaio-Barros PD, Goncalves CR, Borba EF, Timenetsky Mdo C, Precioso AR, Duarte A, Bonfa E, Laurindo IM.
    Ann Rheum Dis; 2011 Dec 19; 70(12):2144-7. PubMed ID: 21859696
    [Abstract] [Full Text] [Related]

  • 12. Pandemic influenza vaccination elicits influenza-specific CD4+ Th1-cell responses in hypogammaglobulinaemic patients: four case reports.
    Pedersen G, Halstensen A, Sjursen H, Naess A, Kristoffersen EK, Cox RJ.
    Scand J Immunol; 2011 Aug 19; 74(2):210-8. PubMed ID: 21438900
    [Abstract] [Full Text] [Related]

  • 13. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients.
    Bickel M, von Hentig N, Wieters I, Khaykin P, Nisius G, Haberl A, Stephan C, Herrmann E, Doerr HW, Brodt HR, Allwinn R.
    Clin Infect Dis; 2011 Jan 01; 52(1):122-7. PubMed ID: 21148530
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity and efficacy in hemodialysis patients of an AS03(A)-adjuvanted vaccine for 2009 pandemic influenza A(H1N1): a nonrandomized trial.
    Dikow R, Eckerle I, Ksoll-Rudek D, Hampel H, Schwenger V, Zeier M, Schnitzler P, Sommerer C.
    Am J Kidney Dis; 2011 May 01; 57(5):716-23. PubMed ID: 21349617
    [Abstract] [Full Text] [Related]

  • 15. Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: a phase III open-label single-arm study.
    Loebermann M, Anders G, Brestrich G, Fritzsche C, Klammt S, Boršo D, Frimmel S, Riebold D, Reisinger EC.
    Vaccine; 2011 Feb 01; 29(6):1228-34. PubMed ID: 21167116
    [Abstract] [Full Text] [Related]

  • 16. Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naïve ferrets.
    Baras B, de Waal L, Stittelaar KJ, Jacob V, Giannini S, Kroeze EJ, van den Brand JM, van Amerongen G, Simon JH, Hanon E, Mossman SP, Osterhaus AD.
    Vaccine; 2011 Mar 03; 29(11):2120-6. PubMed ID: 21238573
    [Abstract] [Full Text] [Related]

  • 17. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab.
    Arad U, Tzadok S, Amir S, Mandelboim M, Mendelson E, Wigler I, Sarbagil-Maman H, Paran D, Caspi D, Elkayam O.
    Vaccine; 2011 Feb 11; 29(8):1643-8. PubMed ID: 21211590
    [Abstract] [Full Text] [Related]

  • 18. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial.
    Wu J, Liu SZ, Dong SS, Dong XP, Zhang WL, Lu M, Li CG, Zhou JC, Fang HH, Liu Y, Liu LY, Qiu YZ, Gao Q, Zhang XM, Chen JT, Zhong X, Yin WD, Feng ZJ.
    Vaccine; 2010 Aug 31; 28(38):6221-7. PubMed ID: 20638454
    [Abstract] [Full Text] [Related]

  • 19. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.
    Radosević K, Rodriguez A, Mintardjo R, Tax D, Bengtsson KL, Thompson C, Zambon M, Weverling GJ, Uytdehaag F, Goudsmit J.
    Vaccine; 2008 Jul 04; 26(29-30):3640-6. PubMed ID: 18514980
    [Abstract] [Full Text] [Related]

  • 20. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab.
    Kaine JL, Kivitz AJ, Birbara C, Luo AY.
    J Rheumatol; 2007 Feb 04; 34(2):272-9. PubMed ID: 17304653
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.